A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1) RISK MYELODYSPLASTIC SYNDROMES (MDS)

被引：0
|
作者：
Platzbecker, U. [1 ]
Symeonidis, A. [2 ]
Oliva, E. [3 ]
Goede, J. [4 ,5 ]
Delforge, M. [6 ]
Mayer, J. [7 ,8 ]
Slama, B. [9 ]
Badre, S. [10 ]
Gasal, E. [11 ]
Mehta, B. [11 ]
Franklin, J. [11 ]
机构：
[1] Univ Hosp Carl Gustav Carus Dresden, Med Klin & Poliklin 1, Dresden, Germany
[2] Univ Patras, Div Hematol, Dept Internal Med, Med Sch, Patras, Greece
[3] Azienda Osped Bianchi Melacrino Morelli, Div Hematol, Reggio Di Calabria, Italy
[4] Univ Hosp, Div Hematol, Zurich, Switzerland
[5] Univ Zurich, Zurich, Switzerland
[6] Univ Hosp Leuven, Hematol, Leuven, Belgium
[7] Masaryk Univ, Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic
[8] Masaryk Univ, Fac Med, Dept Internal Med Hematol & Oncol, Brno, Czech Republic
[9] Ctr Hosp Dept, Oncol Med Hematol Clin, Avignon, France
[10] Amgen Inc, Global Biostat, Thousand Oaks, CA 91320 USA
[11] Amgen Inc, Global Dev, Thousand Oaks, CA 91320 USA
来源：
LEUKEMIA RESEARCH | 2017年 / 55卷
关键词：
D O I：
10.1016/S0145-2126(17)30155-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
42
引用
收藏
页码：S29 / S30
页数：2
相关论文
共 50 条
  • [1] A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1) RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Platzbecker, U.
    Symeonidis, A.
    Oliva, E.
    Goede, J.
    Delforge, M.
    Mayer, J.
    Slama, B.
    Badre, S.
    Gasal, E.
    Mehta, B.
    Franklin, J.
    [J]. HAEMATOLOGICA, 2017, 102 : 484 - 484
  • [2] A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in the Treatment of Anemia in Patients with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndromes (MDS)
    Platzbecker, Uwe
    Symeonidis, Argiris
    Oliva, Esther N.
    Goede, Jeroen S.
    Delforge, Michel
    Mayer, Jiri
    Slama, Borhane
    Badre, Sejal
    Gasal, Eduard
    Mehta, Bhakti
    Franklin, Janet
    [J]. BLOOD, 2016, 128 (22)
  • [3] ARCADE (20090160): A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN THE TREATMENT OF ANEMIA IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Platzbecker, U.
    Symeonidis, A.
    Oliva, E.
    Goede, J. S.
    Delforge, M.
    Mayer, J.
    Badre, S.
    Gasal, E.
    Mehta, B.
    Franklin, J.
    [J]. HAEMATOLOGICA, 2016, 101 : 15 - 15
  • [4] Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Results of a Randomized, Double-Blind, Placebo(PBO)-Controlled Study
    Giagounidis, Aristoteles
    Mufti, Ghulam J.
    Kantarjian, Hagop M.
    Fenaux, Pierre
    Sekeres, Mikkael A.
    Szer, Jeffrey
    Kuendgen, Andrea
    Platzbecker, Uwe
    Gaidano, Gianluca
    Jedrzejczak, Wieslaw
    Hu, Kuolung
    Yang, Allen S.
    Jun, Susie
    [J]. BLOOD, 2011, 118 (21) : 57 - 58
  • [5] An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)
    Platzbecker, Uwe
    Symeonidis, Argiris
    Goede, Jeroen Simon
    Guerci-Bresler, Agnes
    Delforge, Michel
    Oliva, Esther Natalie
    Mayer, Jiri
    Badre, Sejal
    Mehta, Bhakti
    Brandao, Cisio De Oliveira
    [J]. BLOOD, 2017, 130
  • [6] Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study
    Kantarjian, Hagop M.
    Mufti, Ghulam J.
    Fenaux, Pierre
    Sekeres, Mikkael A.
    Szer, Jeffrey
    Platzbecker, Uwe
    Kuendgen, Andrea
    Gaidano, Gianluca
    Wiktor-Jedrzejczak, Wieslaw
    Bennett, John M.
    Meibohm, Anne
    Yang, Allen S.
    Giagounidis, Aristoteles
    [J]. BLOOD, 2012, 120 (21)
  • [7] ARCADE (20090160): A randomized controlled trial of darbepoetin alpha in anemic patients with low or intermediate-1 risk myelodysplastic syndrome (MDS)
    Gasal, E.
    Pan, C.
    Tankersley, C.
    [J]. LEUKEMIA RESEARCH, 2013, 37 : S166 - S167
  • [8] A Randomized Study to Determine the Optimal Dose of Darbepoetin Alfa in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes
    Harada, Hironori
    Shibayama, Hirohiko
    Jang, Jun Ho
    Shimazaki, Ryutaro
    Mitani, Kinuko
    Sawada, Kenichi
    Kim, Hyeoung-Joon
    [J]. BLOOD, 2014, 124 (21)
  • [9] Romiplostim in Thrombocytopenic Patients (Pts) with Low-Risk or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) Results in Reduced Bleeding without Impacting Leukemic Progression: Updated Follow-up Results from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study
    Kantarjian, Hagop
    Mufti, Ghulam J.
    Fenaux, Pierre
    Sekeres, Mikkael A.
    Szer, Jeffrey
    Platzbecker, Uwe
    Kuendgen, Andrea
    Gaidano, Gianluca
    Wiktor-Jedrzejczak, Wieslaw
    Franklin, Janet
    Giagounidis, Aristoteles
    [J]. BLOOD, 2015, 126 (23)
  • [10] Acquisition of Cytogenetic Abnormalities (CA) Is a Very Poor Prognostic Feature in Patients (pts) with Low and Intermediate-1 (int-1) Risk Myelodysplastic Syndromes (MDS)
    Jabbour, Elias
    Kantarjian, Hagop M.
    Wang, Xuemei
    Abruzzo, Lynne V.
    Cornelison, A. Megan
    O'Brien, Susan
    Ravandi, Farhad
    Kadia, Tapan
    Borthakur, Gautam
    Estrov, Zeev
    Cortes, Jorge E.
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2011, 118 (21) : 1624 - 1624
12345